The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss medications Ozempic and Wegovy was linked with a near halving of reported pain ...

Dr Lotte Knudson, a scientist from Copenhagen, revolutionized research into drugs used by millions to lose weight. She has ...

A clinical trial funded by Novo Nordisk found that Ozempic (semaglutide) was linked with reduced pain among patients with ...

Researchers found a significant reduction in the risk for a first-time AD diagnosis in association with semaglutide.

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...

Semaglutide was linked to a significantly reduced risk, most strongly compared with insulin and most weakly with other GLP-1 RAs.

Semaglutide, the weight management drug sold as Ozempic and Wegovy, may reduce the risk of Alzheimer's disease by 40% to 70% ...

In this week’s Bloom Boost – health news you might have missed, Gayle Guyardo , the host of the nationally syndicated health ...

Novo Nordisk said on Friday its weight-loss drug Wegovy met the main goal of a late-stage trial by showing improvement in liver fibrosis with no worsening of steatohepatitis.

Compared to other anti-diabetic drugs, semaglutide, also known as Ozempic, may lower the risk of Alzheimer’s disease in ...

Ozempic and Wegovy, made by Novo Nordisk, are now listed as available across all doses on the FDA’s drug shortage list. But ...